Biotechnology News and Research

RSS

BIOTECH Development Partners provides funds to Biomagnetics

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has begun receiving funds from a biotech-oriented investment group called BIOTECH Development Partners, LLC.

20 Apr 2011

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

Whole-genome sequencing could soon improve cancer survival rates

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

20 Apr 2011

Cmed Group selected to help PDPs develop new medicines in Third-World Countries

Cmed Group, an innovative clinical trials services and advanced software provider, announced today that it has been selected as one of six preferred providers offering its clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The PDPs are working to develop and deliver affordable treatments and vaccines that will help improve the lives of the some of the world's most vulnerable people, especially those in developing countries.

20 Apr 2011

Sialix announces blood test results for early detection and treatment of breast cancer

Sialix, Inc. a pioneer in glycobiology, today announced the results of a study it participated in with researchers at the University of California, San Diego School of Medicine that could have significant impact in the prediction, early detection and treatment of cancer in humans.

20 Apr 2011

Medtronic launches MARROWMAX Bone Marrow Aspiration Needle Kit in the U.S.

Expanding its leading bone grafting portfolio, Medtronic, Inc. today announced the U.S. launch of the MARROWMAX™ Bone Marrow Aspiration Needle Kit.

20 Apr 2011

Sartorius first-quarter sales revenue increases 14.4% to 172.1 million euros

Sartorius started off fiscal 2011 with double-digit growth rates in order intake, sales revenue and profit. "We are currently seeing dynamic growth fueled by both divisions and all business regions. Compared with the year-earlier quarter, though also slightly below average, we have achieved highly encouraging rates of increase in revenue and profit," said CEO Dr. Joachim Kreuzburg.

From Sartorius 20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.

20 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

EraGen, Applied BioCode partner to commercialize molecular diagnostics

Applied BioCode, Inc. and EraGen Biosciences Inc. today announced that they have entered into a strategic partnership and license agreement. The agreement provides EraGen with access to Applied BioCode's Barcoded Magnetic Bead technology and the CE-marked BioCode-1000 system.

19 Apr 2011

Circassia closes $98 million fundraising for lead allergy programmes

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.

19 Apr 2011

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

NIH awards U of M's scientist with $10 million grant for HIV research

Reuben Harris, professor in the University of Minnesota's College of Biological Sciences, has been awarded a five-year, $10 million grant from the National Institutes of Health to direct a large-scale research effort to study a human antiviral protein with potential for treating HIV and other viral diseases.

19 Apr 2011

Ahram Biosystems launches portable Palm PCR thermocycler system

Ahram Biosystems, Inc., a leading innovator of new life science tools, today announced the launch of the Palm PCR system, an innovative portable PCR device that delivers high performance nucleic acid amplification in a small handheld format.

18 Apr 2011